Helmholtz Association

MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA Services

Retrieved on: 
Tuesday, September 26, 2023
GMP, Sigma-Aldrich, Körber Process Solutions, Lipid, Cancer, Believer, Max, Merck Group, ECRC, Research, Experiment, Messenger, Molecular medicine, Helmholtz Association, Mab, Growth, Merck, Spacecraft, LNP, A-DNA, Muscular dystrophy, Vaccine, Pharmaceutical industry, BURLINGTON

The company today opened two new GMP-grade mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany.

Key Points: 
  • The company today opened two new GMP-grade mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany.
  • "We are now the first CTDMO to streamline the entire mRNA process for our clients."
  • MilliporeSigma also offers differentiated PCR-based technology for clinical and commercial mRNA manufacturing, providing clients with high-quality mRNA.
  • Its unique combination of mRNA expertise, technologies, regulatory knowledge, and product portfolios streamlines mRNA manufacturing and testing.

Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology

Retrieved on: 
Monday, September 25, 2023
Lymphoma, Antigen, CSO, Colon cancer staging, Neoplasm, Max, Breast, NK, Prostate, Antibody, Lung, Molecular medicine, CAR, Incidence, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Hematological Cancer Research Investment and Education Act, Patient, Helmholtz Association, Mortality, Lymphocyte, Leukemia, Glycosylation, Uta, Epidemiology of cancer, Vaccine, Autoimmunity, Cancer

Berlin, Germany, 25 September 2023 – Glycotope GmbH (Glycotope) and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.

Key Points: 
  • Berlin, Germany, 25 September 2023 – Glycotope GmbH (Glycotope) and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.
  • However, in some indications, including harder to treat cancers with solid tumors, success has been limited.
  • In the scope of the newly established collaboration, highly tumor-specific antibodies developed by Glycotope will be combined with the CAR technology of the Max Delbrück Center to analyze their suitability for the treatment of solid tumors.
  • The CAR program at the Max Delbrück Center includes several proprietary antibody binders targeting hematologic tumors.

DDN and Helmholtz Munich Receive 2023 Artificial Intelligence Breakthrough Award

Retrieved on: 
Wednesday, June 21, 2023
Data management, University, Ministry of Telecommunication, Digital Infrastructure and Foreign Employment, Research, Organization, Science, Helmholtz Association, DDN, Risk, Machine learning, Drug discovery, Big data, BASF, Artificial intelligence, Architecture, SFA, AI, Health, GPU, University of Oxford, Medical device

CHATSWORTH, Calif., June 21, 2023 /PRNewswire/ -- DDN®, the global leader in artificial intelligence (AI) and multi-cloud data management solutions, today announced it has been selected alongside Helmholtz Munich as a winner of the 2023 AI Breakthrough Awards for the "Best AI-based Solution for Life Sciences" category. DDN and Helmholtz Munich were recognized for their work in accelerating AI-driven discoveries that deliver concrete benefits to society and human health.

Key Points: 
  • CHATSWORTH, Calif., June 21, 2023 /PRNewswire/ -- DDN® , the global leader in artificial intelligence (AI) and multi-cloud data management solutions, today announced it has been selected alongside Helmholtz Munich as a winner of the 2023 AI Breakthrough Awards for the "Best AI-based Solution for Life Sciences" category.
  • DDN and Helmholtz Munich were recognized for their work in accelerating AI-driven discoveries that deliver concrete benefits to society and human health.
  • Together, DDN and Helmholtz Munich are trailblazing their way through Life Science discovery, and we are thrilled to recognize DDN and Helmholtz Munich in the 2023 AI Breakthrough Awards program."
  • A list of all the featured winners for the 2023 AI Breakthrough Awards can be found here: AI Breakthrough 2023 Award Winners .

The Mark Foundation for Cancer Research Appoints Two New Members to Board of Directors

Retrieved on: 
Wednesday, May 10, 2023
Advertising, Korn Ferry, Follicular lymphoma, Meta, Workplace, Picturehouse (band), World Cancer Day, Cancer, DKFZ, Research, German Cancer Aid, German Cancer Research Center, Doctor of Philosophy, Nicola, BBH, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Othmar, National Executive Board of the Boy Scouts of America, Science, Patient, Helmholtz Association, Memorial Sloan Kettering Cancer Center, Diagnosis, Mendelssohn (surname), Pharmaceutical industry, Management, Diageo, MD

NEW YORK, May 10, 2023 /PRNewswire/ -- The Mark Foundation for Cancer Research announced today the appointment of two new members to its Board of Directors. Nicola Mendelsohn CBE, Head of Global Business at Meta, and Otmar Wiestler, MD, President of the Helmholtz Association, Germany's largest scientific organization, were elected at The Mark Foundation's April board meeting. Their terms are effective immediately. Both new board members are well-positioned and uniquely qualified to support the Foundation's mission of accelerating research that will transform the prevention, diagnosis, and treatment of cancer.

Key Points: 
  • Nicola Mendelsohn CBE, Head of Global Business Group at Meta, and Otmar Wiestler, President of Helmholtz Association, join board of global leader in cancer research funding
    NEW YORK, May 10, 2023 /PRNewswire/ -- The Mark Foundation for Cancer Research announced today the appointment of two new members to its Board of Directors.
  • Both new board members are well-positioned and uniquely qualified to support the Foundation's mission of accelerating research that will transform the prevention, diagnosis, and treatment of cancer.
  • "We are honored to welcome these distinguished members to The Mark Foundation Board of Directors," said Ray DuBois, MD, PhD, Executive Chairman.
  • "The Mark Foundation is committed to accelerating cancer research on a global scale; since 2017 they have funded outstanding grantees in 13 countries," said Otmar Wiestler.

DDN Selected by Helmholtz Munich to Accelerate AI-Driven Discoveries Delivering Concrete Benefits to Society and Human Health

Retrieved on: 
Wednesday, May 10, 2023
Data management, Ministry of Telecommunication, Digital Infrastructure and Foreign Employment, Marketing, Research, Science, Helmholtz Association, DDN, Risk, Big data, Artificial intelligence, Architecture, SFA, Health, GPU, Medical device

CHATSWORTH, Calif., May 10, 2023 /PRNewswire/ -- DDN®, the global leader in artificial intelligence (AI) and multi-cloud data management solutions, today announced Helmholtz Munich has selected DDN to accelerate its AI-driven discoveries. As part of the Helmholtz Association, Germany's largest research organization, Helmholtz Munich is one of 19 research centers that develops solutions and technologies for the world of tomorrow. The research integrates AI methodologies and spans multiple data-intensive computational applications like decoding plant genomes, tissue sample testing or creature and epidemiology cohort studies.

Key Points: 
  • CHATSWORTH, Calif., May 10, 2023 /PRNewswire/ -- DDN ® , the global leader in artificial intelligence (AI) and multi-cloud data management solutions, today announced Helmholtz Munich has selected DDN to accelerate its AI-driven discoveries.
  • "The knowledge that Helmholtz Munich gains from its research forms the foundation of tomorrow's medicine and delivers concrete benefits to society and improvements to human health," said Dr. Alf Wachsmann, head of DigIT Infrastructure & Scientific Computing, Helmholtz Munich.
  • "DDN is honored to assist Helmholtz Munich by delivering solutions that allow its researchers to focus on the scientific discoveries that improve the world of tomorrow."
  • Click here to learn more about Helmholtz Munich's infrastructure challenges and the immediate benefits of implementing the DDN systems to accelerate the cutting-edge biomedical research taking place in Germany.

40-million-euro sustainable kerosene research project CARE-O-SENE receives funding

Retrieved on: 
Wednesday, October 12, 2022
Chemicals, Plastics, Energy, Manufacturing, Oil, Gas, Hydrogen, Education, Helmholtz-Zentrum Berlin, BESSY, GSI Helmholtz Centre for Heavy Ion Research, Helmholtz Association, PTL, Federal Ministry of Science and Technology, Aviation, Catalysis, Carbon, Fischer–Tropsch process, Cosmetics, Multimedia, KIT, Aviation biofuel, Karlsruhe Institute of Technology, Technology, Solution, Detergent, SAF, Government College of Engineering and Ceramic Technology, Industry, German, Association, HZB, Kerosene, BMBF, Fraunhofer Society, University, African, Operando spectroscopy, UCT, Jet fuel, Research

The international research project CARE-O-SENE (Catalyst Research for Sustainable Kerosene) was granted 30 million euros in funding by the German Federal Ministry of Education and Research (BMBF).

Key Points: 
  • The international research project CARE-O-SENE (Catalyst Research for Sustainable Kerosene) was granted 30 million euros in funding by the German Federal Ministry of Education and Research (BMBF).
  • The aim of the project is to develop novel, next-generation Fischer-Tropsch catalysts and thus to optimise the production of sustainable kerosene or Sustainable Aviation Fuel (SAF) on an industrial scale.
  • View the full release here: https://www.businesswire.com/news/home/20221012005528/en/
    Sustainable kerosene is not based on fossil-based raw materials like conventional kerosene but on green hydrogen and carbon dioxide.
  • We are delighted that the BMBF has recognised the enormous potential in the CARE-O-SENE research project on the novel Fischer-Tropsch catalysts and supports the work.

FONDAZIONE PRADA PRESENTS "HUMAN BRAINS: PRESERVING THE BRAIN - FORUM ON NEURODEGENERATIVE DISEASES"

Retrieved on: 
Tuesday, September 6, 2022
Harvard Medical School, Lists of diseases, Max Planck Institute of Neurobiology, Helmholtz Association, University, University College London, Consciousness, Fondazione Prada, Research, Exhibition, Multiple sclerosis, Tianjin Medical University General Hospital, DZNE, Amyotrophic lateral sclerosis, Cone Health Women's Hospital, Lebanese Army Teaching Institute, German Center for Neurodegenerative Diseases, Yale School of Medicine, Weizmann Institute of Science, Organization, Alzheimer's disease, Neurodegeneration, Hospital, Neurology, History, Knowledge, Association, Human, Medical device, Pharmaceutical industry, Medicine, Brain, Brigham, Neuroscience

The fourth phase of "Human Brains, titled "Preserving the Brain Forum on Neurodegenerative Diseases", will comprise an exhibition (16 September 10 October 2022) and a conference (6 and 7 October 2022) at Fondazione Prada's Milan premises.

Key Points: 
  • The fourth phase of "Human Brains, titled "Preserving the Brain Forum on Neurodegenerative Diseases", will comprise an exhibition (16 September 10 October 2022) and a conference (6 and 7 October 2022) at Fondazione Prada's Milan premises.
  • "Preserving the Brain" aims to stimulate an open and critical exchange between internationalscientists and experts on neurodegenerative diseases, such as Alzheimer's, Parkinson's,Amyotrophic lateral sclerosis and Multiple sclerosis, which are widely spread and as yetincurable.
  • 'Preserving the Brain' also demonstrates how critical collaboration and sharing of knowledge are within the scientific community.
  • The pivotal moment of "Preserving the Brain" will be the scientific conference held on 6 and 7 October 2022, at Fondazione Prada's Cinema in Milan.

FONDAZIONE PRADA PRESENTS "HUMAN BRAINS: PRESERVING THE BRAIN - FORUM ON NEURODEGENERATIVE DISEASES"

Retrieved on: 
Tuesday, September 6, 2022
Harvard Medical School, Lists of diseases, Max Planck Institute of Neurobiology, Helmholtz Association, University, University College London, Consciousness, Fondazione Prada, Research, Exhibition, Multiple sclerosis, Tianjin Medical University General Hospital, DZNE, Amyotrophic lateral sclerosis, Cone Health Women's Hospital, Lebanese Army Teaching Institute, German Center for Neurodegenerative Diseases, Yale School of Medicine, Weizmann Institute of Science, Organization, Alzheimer's disease, Neurodegeneration, Hospital, Neurology, History, Knowledge, Association, Human, Medical device, Pharmaceutical industry, Medicine, Brain, Brigham, Neuroscience

The fourth phase of "Human Brains, titled "Preserving the Brain Forum on Neurodegenerative Diseases", will comprise an exhibition (16 September 10 October 2022) and a conference (6 and 7 October 2022) at Fondazione Prada's Milan premises.

Key Points: 
  • The fourth phase of "Human Brains, titled "Preserving the Brain Forum on Neurodegenerative Diseases", will comprise an exhibition (16 September 10 October 2022) and a conference (6 and 7 October 2022) at Fondazione Prada's Milan premises.
  • "Preserving the Brain" aims to stimulate an open and critical exchange between internationalscientists and experts on neurodegenerative diseases, such as Alzheimer's, Parkinson's,Amyotrophic lateral sclerosis and Multiple sclerosis, which are widely spread and as yetincurable.
  • 'Preserving the Brain' also demonstrates how critical collaboration and sharing of knowledge are within the scientific community.
  • The pivotal moment of "Preserving the Brain" will be the scientific conference held on 6 and 7 October 2022, at Fondazione Prada's Cinema in Milan.

The BioInnovation Institute supports three international start-ups developing pioneering science in the therapeutics and health tech space

Retrieved on: 
Monday, August 22, 2022
Chronic pain, Helmholtz Association, Berlin Institute for Population and Development, Pain, Degenerative disease, Research, Novo Nordisk Foundation, Therapy, Solution, GDPR, EUR, Hospital, Molecular medicine, Acceleration, BII, Association, Drug development, Growth, Sevenless, Patient, Pharmaceutical industry, Film

The three new ventures are strategically aligned with the BII's focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space.

Key Points: 
  • The three new ventures are strategically aligned with the BII's focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space.
  • Spun out from excellent translational research environments across Europe, VEIL.AI, Myopax and Sevenless Therapeutics each hold great potential in the therapeutic and health tech space.
  • It enables better use of GDPR-free data for life science and diagnostics companies, hospitals and health data hubs.
  • The BioInnovation Institute Foundation (BII) is an international commercial foundation with a nonprofit objective supported by the Novo Nordisk Foundation.

The BioInnovation Institute supports three international start-ups developing pioneering science in the therapeutics and health tech space

Retrieved on: 
Monday, August 22, 2022
Chronic pain, Helmholtz Association, Berlin Institute for Population and Development, Pain, Degenerative disease, Research, Novo Nordisk Foundation, Therapy, Solution, GDPR, EUR, Hospital, Molecular medicine, Acceleration, BII, Association, Drug development, Growth, Sevenless, Patient, Pharmaceutical industry, Film

The three new ventures are strategically aligned with the BII's focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space.

Key Points: 
  • The three new ventures are strategically aligned with the BII's focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space.
  • Spun out from excellent translational research environments across Europe, VEIL.AI, Myopax and Sevenless Therapeutics each hold great potential in the therapeutic and health tech space.
  • It enables better use of GDPR-free data for life science and diagnostics companies, hospitals and health data hubs.
  • The BioInnovation Institute Foundation (BII) is an international commercial foundation with a nonprofit objective supported by the Novo Nordisk Foundation.